About AccuTheranostics
AccuTheranostics is a Healthcare company based in Buffalo (United States) founded in 2012 by Steven Cerne, Arvind Thakur, and Sherry Bradford. Personalized chemotherapy response testing is offered for cancer patients. Its chief executive, as recorded, is Steven Cerne. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its competitors include Denali Therapeutics, MiRagen and Poseida Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
AccuTheranostics was founded in 2012 and is headquartered in Buffalo, United States. The company operates in the healthcare sector, focusing on oncology and personalized medicine. Laboratory tests, including the ChemoFit assay, are developed to evaluate individual patient responses to chemotherapy drugs. These services assist medical professionals in selecting appropriate treatments for cancer patients based on biological data.
- Headquarters Buffalo, United States
- Founders Steven Cerne, Arvind Thakur, Sherry Bradford
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website accutheranostics.com
- Social LinkedIn
- Latest Funding Round$50K (USD), Grant
Sep 2016
- Investors
Funding Insights of AccuTheranostics
- Total Rounds 1
- Last Round Grant — $50,000
- First Round $50,000
(Sep 2016)
- Investors Count 1
All 1 funding rounds of AccuTheranostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2016 | $50,000 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in AccuTheranostics
AccuTheranostics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Launch NY.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Launch NY is focused on supporting high-growth startups in Upstate New York. | launchny.org | Buffalo, United States |
Investor details for AccuTheranostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AccuTheranostics
3 people are tracked at AccuTheranostics (3 in leadership).
| Name | Role | Group |
|---|---|---|
Steven Cerne | Co-Founder & CEO | Leadership |
Arvind Thakur | Co-Founder | Leadership |
Sherry Bradford | Co-Founder | Leadership |
Complete people profiles for AccuTheranostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AccuTheranostics
2 dated milestones of AccuTheranostics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded AccuTheranostics is founded.
- Funding First funding round of $50K.
Competitors of AccuTheranostics
AccuTheranostics has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, MiRagen and Poseida Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies |
Detailed competitors of AccuTheranostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AccuTheranostics
Websites that share an audience with AccuTheranostics (accutheranostics.com).
Websites whose visitors overlap most with AccuTheranostics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as AccuTheranostics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AccuTheranostics
AccuTheranostics was founded in 2012 and raised its 1st funding round 4 years after it was founded.
AccuTheranostics is headquartered in Buffalo, United States. It is registered at Buffalo, New York, United States.
Steven Cerne is the CEO of AccuTheranostics, as recorded in our data. They have also founded this company.
AccuTheranostics was founded in 2012 and is headquartered in Buffalo, United States. The company operates in the healthcare sector, focusing on oncology and personalized medicine. Laboratory tests, including the ChemoFit assay, are developed to evaluate individual patient responses to chemotherapy drugs. These services assist medical professionals in selecting appropriate treatments for cancer patients based on biological data.
AccuTheranostics's top competitors include Poseida Therapeutics, Denali Therapeutics and MiRagen.
AccuTheranostics has 1 investor. Key investors include Launch NY.